Prostaglandins & other lipid mediators · 2025
The role of eicosapentaenoic acid-loaded nanoparticles on alleviating drug resistance in xenograft breast cancer model.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Elsayed Fatma F, Abo-Elmatty Dina M, El-Khayat Zakaria, Tolba Emad, Wahba Alaa S, Hussien Jihan
Аннотация
BACKGROUND: Multidrug resistance (MDR) is a major dilemma in the effective chemotherapy treatment of breast cancer. Potential strategies to combat MDR include inhibiting efflux pumps such as ATP-binding cassette (ABC) transporters and calcium channel pumps like transient receptor potential (TRP) channels and blocking the metastatic pathway by inhibiting the antiapoptotic proteins like Bcl-2, while enhancing the apoptotic proteins like caspase-3.
RESULTS: The results demonstrated that treatment with either EPA or EPA/PCL led to a marked suppression of doxorubicin resistance, as evidenced by a significant reduction in tumor size, measured by caliper, in the treated groups over the course of the experiment. Furthermore, the combination of EPA or EPA-loaded PCL with DOX modulated the expression of drug resistance genes and apoptotic pathways by targeting transient receptor potential canonical 5 (TRPC5), P-glycoprotein (P-gp), and Bcl-2, while simultaneously enhancing the expression of caspase-3. Additionally, nano-characterization of the PCL particles using transmission electron microscopy (TEM), dynamic light scattering (DLS), and zeta potential analysis demonstrated their favorable stability and physicochemical properties.
CONCLUSION: The present study investigated the effect of eicosapentaenoic acid (EPA)-loaded polycaprolactone (PCL) in overcoming drug resistance when used in combination with doxorubicin (DOX), as compared to DOX alone and EPA in its original form. Interestingly, it reveals a promising approach to ameliorate the resistance of Doxorubicin in breast cancer.
RESULTS: The results demonstrated that treatment with either EPA or EPA/PCL led to a marked suppression of doxorubicin resistance, as evidenced by a significant reduction in tumor size, measured by caliper, in the treated groups over the course of the experiment. Furthermore, the combination of EPA or EPA-loaded PCL with DOX modulated the expression of drug resistance genes and apoptotic pathways by targeting transient receptor potential canonical 5 (TRPC5), P-glycoprotein (P-gp), and Bcl-2, while simultaneously enhancing the expression of caspase-3. Additionally, nano-characterization of the PCL particles using transmission electron microscopy (TEM), dynamic light scattering (DLS), and zeta potential analysis demonstrated their favorable stability and physicochemical properties.
CONCLUSION: The present study investigated the effect of eicosapentaenoic acid (EPA)-loaded polycaprolactone (PCL) in overcoming drug resistance when used in combination with doxorubicin (DOX), as compared to DOX alone and EPA in its original form. Interestingly, it reveals a promising approach to ameliorate the resistance of Doxorubicin in breast cancer.